Wednesday, August 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 12, 2026

S&P 500 Update This Week: 4 Signals to Watch After Delta's Earnings

View original at nasdaq.com
S&P 500 Update This Week: 4 Signals to Watch After Delta's Earnings Key Points Delta Air Lines proved that strong operators can deliver under direct cost pressure, but most companies aren’t built to absorb shocks like fuel cost surges…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Procter & Gamble guided for 0% to 4% organic sales growth for the remainder of the year

    60% confidence
  • Identified 10 best stocks for investors to buy now, and Delta Air Lines was not one of them

    60% confidence
  • Upward pressure on oil prices could linger, and any renewed conflict could send prices toward the $120 to $130 range

    60% confidence
  • Colgate-Palmolive downgraded from Buy to Hold with price target cut from $96 to $85 due to oil-based input costs surging 33.9% in a single month and tallow prices up 40% year over year

    60% confidence

Data points we hold from this source

Procter & Gamble · ytd return2 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com